31.10.2019 21:14:41

Amgen To Acquire 20.5% Stake In BeiGene For Approx. $2.7 Bln - Quick Facts

(RTTNews) - Amgen (AMGN) has entered into a strategic collaboration with BeiGene that will accelerate Amgen's plans to expand its oncology presence in China. BeiGene is a research-based, oncology-focused biotechnology company. Amgen will acquire a 20.5 percent stake in BeiGene for approximately $2.7 billion. This represents a purchase price of $174.85 per BeiGene American Depositary Share on NASDAQ.

Amgen and BeiGene will collaborate to advance 20 medicines from Amgen's oncology pipeline in China and globally. BeiGene will share global research and development costs and contribute up to $1.25 billion. Amgen will pay royalties to BeiGene on the sales of these products outside of China.

Analysen zu Amgen Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Amgen Inc. 273,90 0,37% Amgen Inc.
BeiGene Ltd (spons. ADRs) 218,00 0,00% BeiGene Ltd (spons. ADRs)